The Antiandrogen Enzalutamide Downregulates TMPRSS2 and Reduces Cellular Entry of SARS-CoV-2 in Human Lung Cells

Researchers showed that treatment with the antiandrogen enzalutamide—a well-tolerated drug widely used in advanced prostate cancer—reducesd transmembrane serine protease 2 (TMPRSS2) levels in human lung cells and in mouse lung.